Action Novus Therapeutics - NVUS

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

14,60

Prix Achat

14,65

Prix Vente

21,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

353,291M

Clôture Veille

14,60

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

24 198 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,77

Bénéfice par action (BPA)

-1,67

Chiffre d'affairess

Bénéfice net

-40,33M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.eledon.com

Siège social

Dover, Delaware, USA

Fondé

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic ...

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted...

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of...

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential...

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular...

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage...

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of...

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire IRVINE, California, Nov. 21, 2017 IRVINE...

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire IRVINE, California, Nov. 8, 2017 IRVINE, California, Nov. 8, 2017 /PRNewswire/...

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire IRVINE, Calif., Nov. 8, 2017 IRVINE, Calif., Nov. 8, 2017 /PRNewswire/ -- Novus...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

NVUS - Frequently Asked Questions (FAQ)

What is the current Novus Therapeutics share price?

The current share price of Novus Therapeutics is US$ 14,60

How many Novus Therapeutics shares are in issue?

Novus Therapeutics has 24 198 000 shares in issue

What is the market cap of Novus Therapeutics?

The market capitalisation of Novus Therapeutics is USD 353,29M

What is the 1 year trading range for Novus Therapeutics share price?

Novus Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Novus Therapeutics?

The price to earnings ratio of Novus Therapeutics is -1,77

What is the reporting currency for Novus Therapeutics?

Novus Therapeutics reports financial results in USD

What is the latest annual profit for Novus Therapeutics?

The latest annual profit of Novus Therapeutics is USD -40,33M

What is the registered address of Novus Therapeutics?

The registered address for Novus Therapeutics is 8 THE GREEN, STE B, KENT, DOVER, DELAWARE, 19901

What is the Novus Therapeutics website address?

The website address for Novus Therapeutics is www.eledon.com

Which industry sector does Novus Therapeutics operate in?

Novus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MSPRMSP Recovery Inc	US$ 2,479 (93,67%)	87,37M
PRTGPortage Biotech Inc	US$ 8,5091 (66,85%)	31,29M
WTOUTime Limited	US$ 2,15 (61,65%)	1,19M
BFRGBullfrog AI Holdings Inc	US$ 2,09 (48,23%)	13,81M
THTXTheratechnologies Inc	US$ 1,94 (45,86%)	49,38M
TOROVToro Corporation	US$ 1,43 (-82,48%)	109,39k
LUCYInnovative Eyewear Inc	US$ 2,3471 (-52,58%)	1,98M
XHGXChange TED Inc	US$ 0,1985 (-45,71%)	8,7M
MULNMullen Automotive Inc	US$ 2,18 (-39,44%)	4,35M
FLDFold Holdings Inc	US$ 2,6601 (-33,50%)	1,74M
DMNDamon Inc	US$ 0,003 (-28,57%)	1,04B
BONBon Natural Life Ltd	US$ 0,066 (8,73%)	653,46M
STSSSharps Technology Inc	US$ 0,0245 (33,88%)	640,47M
NVDANVIDIA Corporation	US$ 110,93 (3,12%)	303,97M
LGMKLogicMark Inc	US$ 0,009699 (3,18%)	261,75M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novus Therapeutics Inc (NVUS)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Novus Therapeutics Inc

NVUS Dernières nouvelles

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic ...

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results

NVUS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novus Therapeutics Inc (NVUS) Cours

Novus Therapeutics Inc (NVUS)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Novus Therapeutics Inc

NVUS Dernières nouvelles

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic ...

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results

NVUS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS